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Malignant astrocytomas are the most common 
and lethal adult primary brain tumors, with Glio-
blastoma Multiforme (GBM) being the most 
aggressive  astrocytoma  (Mahaley  et  al.,  1989; 
Kleihues and Cavanee, 2000). GBMs have been 
categorized into either primary or secondary 
subtypes (Louis et al., 2007). Primary GBMs 
present de novo with no prior evidence of 
symptoms and occur in older patients. In con-
trast,  secondary  GBMs  are  derived  from  the 
progression  of  lower  grade  astrocytomas  and 
occur in younger patients. Surprisingly, despite 
different clinical histories, primary and secondary 
GBMs are morphologically and clinically indis-
tinguishable. In spite of aggressive surgery, ad-
juvant radiation, chemotherapy, and emerging 
biological targeted therapies, the median survival 
of GBM patients is 12–16 mo (Stupp et al., 2005). 
Therefore, identification of molecular alterations 
and their mechanistic role in transformation of 
these tumors has been of long-standing interest. 
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Glioblastoma Multiforme (GBM), the most common and lethal primary human brain tumor, 
exhibits multiple molecular aberrations. We report that loss of the transcription factor 
GATA4, a negative regulator of normal astrocyte proliferation, is a driver in glioma formation 
and fulfills the hallmarks of a tumor suppressor gene (TSG). Although GATA4 was expressed 
in normal brain, loss of GATA4 was observed in 94/163 GBM operative samples and was a 
negative survival prognostic marker. GATA4 loss occurred through promoter hypermethyl-
ation or novel somatic mutations. Loss of GATA4 in normal human astrocytes promoted high-
grade astrocytoma formation, in cooperation with other relevant genetic alterations such as 
activated Ras or loss of TP53. Loss of GATA4 with activated Ras in normal astrocytes pro-
moted a progenitor-like phenotype, formation of neurospheres, and the ability to differenti-
ate into astrocytes, neurons, and oligodendrocytes. Re-expression of GATA4 in human GBM 
cell lines, primary cultures, and brain tumor–initiating cells suppressed tumor growth in vitro 
and in vivo through direct activation of the cell cycle inhibitor P21CIP1, independent of TP53. 
Re-expression of GATA4 also conferred sensitivity of GBM cells to temozolomide, a DNA 
alkylating agent currently used in GBM therapy. This sensitivity was independent of MGMT 
(O-6-methylguanine-DNA-methyltransferase), the DNA repair enzyme which is often impli-
cated in temozolomide resistance. Instead, GATA4 reduced expression of APNG (alkylpurine-
DNA-N-glycosylase), a DNA repair enzyme which is poorly characterized in GBM-mediated 
temozolomide resistance. Identification and validation of GATA4 as a TSG and its downstream 
targets in GBM may yield promising novel therapeutic strategies.
©  2011  Agnihotri  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first 
six  months  after  the  publication  date  (see  http://www.rupress.org/terms).   
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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GATA4/5/6  subfamily. The  GATA 
family of transcription factors consists 
of six members, with two conserved 
zinc  finger  domains  that  recognize 
the  consensus  DNA  binding  motif   
of (A/T)/GATA/(A/G) (Molkentin, 
2000). They regulate biological func-
tions, including organogenesis, differ-
entiation, proliferation, and apoptosis 
(Kuo et al., 1997; Charron et al., 1999; 
Koutsourakis et al., 1999; Holtzinger 
and  Evans,  2005;  Kobayashi  et  al., 
2006; Watt et al., 2007), but their roles 
in the normal and transformed human 
central nervous system (CNS) remain 
in large part unknown.
Our interests have focused on GATA4 and GATA6 because 
we observed no significant alterations in GATA5 expression be-
tween normal brain and HGAs. We have previously reported on 
the expression profile of GATA6 in the CNS (Kamnasaran and 
Guha, 2005) and recently reported GATA4 expression in normal 
embryonic and adult mouse and human astrocytes, in which it 
functions as an inhibitor of proliferation and inducer of apoptosis 
(Agnihotri et al., 2009). GATA4 knockout mice are embryonic 
lethal (embryonic day [E] 7.5–8.5) as a result of cardiac defects 
(Kuo et al., 1997; Pehlivan et al., 1999; Reamon-Buettner et al., 
2007), and GATA4 mutations cause Holt-Oram syndrome and 
congenital heart defects. GATA4 is frequently silenced in lung, 
colon, prostate, ovarian, and breast cancer (Akiyama et al., 2003; 
Guo et al., 2004, 2006; Caslini et al., 2006; Hua et al., 2009), but 
its exact role in cancer biology and the mechanisms by which it 
operates are poorly understood. Given the role of GATA4 in 
regulating astrocyte proliferation and the observed loss of GATA4 
in several human cancers, in this study we demonstrate GATA4 
to be a novel tumor suppressor in GBM, and we identify novel 
mechanisms of tumor suppression regulated by GATA4.
Toward this goal, several approaches have been undertaken, 
including recent genome-wide sequencing approaches, which 
have pointed to a large number of novel and known genetic 
alterations present in GBMs (Cancer Genome Atlas Research 
Network, 2008; Parsons et al., 2008; Verhaak et al., 2010). 
These large-scale studies involving human samples, although 
very informative, still require vigorous evaluation of the func-
tional significance of these alterations.
To identify novel loss of function alterations involved in   
astrocytoma progression, we used a retroviral-mediated gene-
trap mutagenesis screen on nontransformed GFAP:V12Ha-Ras– 
expressing astrocytes isolated from a genetically engineered mouse 
model (GEM), which are born normal but develop low-grade 
astrocytomas (LGAs) and high-grade astrocytomas (HGAs) 
which when characterized are similar to their human counter-
parts (Ding et al., 2001). Using this approach, we identified that 
disruption of GATA6 led to transformation and demonstrated 
that GATA6 is a new and relevant human GBM tumor sup-
pressor gene (TSG; Kamnasaran et al., 2007). This furthered our 
interest  on  the  GATA  transcription  factors,  specifically  the 
Figure 1.  GATA4 loss in GBM. (A) Loss 
of Gata4 observed in primary astrocyte 
cultures from transgenic mice bearing GBM 
tumors at 3 mo (RasB8 P3) compared with 
primary astrocyte cultures from healthy 
newborn pups RasB8 P0 and astrocyte cul-
tures from newborn or adult healthy WT 
mice NMA). (B) Immunoblotting of GATA4, 
GATA5 in human GBM cell lines with NHB, 
NHAs, and immortalized NHAs with telome-
rase (NHA + hTERT) used as positive con-
trols. (C and D) Immunohistochemical 
analysis of GATA4 in normal brain (n = 10, 
positive control), low grade gliomas (n = 29; C), 
and GBM operative specimens (n = 163; D) 
with corresponding H&E stains. (E) Survival 
curve analysis of GATA4-positive and -nega-
tive GATA4 GBM patients (Log-Rank test,  
P = 0.01). Bars: (C) 20 µm; (D) 50 µm. West-
ern blots were performed in triplicate.JEM VOL. 208, April 11, 2011 
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specimens (Fig. 1, C and D). The specificity of the anti-
GATA4 antibody was tested using confirmed GBM tissue 
that did not express GATA4 at the transcript or protein level 
(Fig. S1 A). Tissue microarray analysis of primary GBM linked 
with survival data (Cloughesy et al., 2008 ;Guo et al., 2009;   
n = 43, primary GBM) demonstrated poorer overall survival 
in patients with loss of GATA4 expression, compared with 
patients with GATA4 expression (Fig. 1 E; P = 0.01, Log-rank 
test). In summary, GATA4 loss is observed in a majority of 
human GBM lines and operative samples.
Promoter methylation and somatic mutations silence  
GATA4 expression
To establish the etiology of GATA4 loss in human GBMs, we 
first determined whether there was epigenetic silencing by 
hypermethylation of the GATA4 promoter, as demonstrated 
in lung and colon cancer (Akiyama et al., 2003; Guo et al., 
2004; Hellebrekers et al., 2009). The 1,200-bp GATA4 proximal 
RESULTS
Loss of GATA4 is observed in a majority of GBMs
We  established  nontransformed  primary  astrocyte  cultures 
from normal control mice (newborn normal mouse astrocyte 
[NMA] postnatal day [P] 0 and 3-mo-old NMA P3), both of 
which expressed Gata4 (Fig. 1 A). Cultures derived from our 
newborn GFAP:V12Ha-Ras glioma-prone mice, RasB8 P0, 
expressed Gata4, whereas astrocytoma cultures from 3-mo-old 
tumor-bearing GFAP:V12Ha-Ras mice, RasB8 P3, had complete 
loss of Gata4 (Fig. 1 A). There was no variation in Gata5 ex-
pression between NMAs and mouse astrocytoma cells (Fig. 1 A). 
Complete loss of GATA4 but not GATA5 was observed in 
10/11 human GBM lines compared with normal human 
astrocytes (NHAs) and those which were immortalized but 
not transformed with hTERT (NHA + hTERT; Fig. 1 B). 
We then examined the status of GATA4 expression in patient 
tumor specimens. GATA4 protein expression was lost in 
15/29 (50%) LGAs and 94/163 (60%) human GBM 
Figure 2.  Promoter methylation and mu-
tations result in loss of GATA4 expression. 
(A) GATA4 proximal promoter (1,000 bp 
from transcriptional start site) contains two 
CpG islands. Dashed arrow show location of 
MSP-PCR primers and nondashed arrows 
show location of primers used for bisulfite 
sequencing. MSP-PCR of GATA4 in GBM cell 
lines, NHB, and NHAs is shown. Methylated 
product (M) and unmethylated product (U) 
are indicated. (B) GBM cell lines were treated 
with 5-aza-2’-deoxycytidine (5 µm final con-
centration, abbreviated ± A for 96 h) and 
GATA4 protein measured by Western blot.  
(C) Bisulfite sequencing represented as a heat 
map demonstrates that lack of GATA4 tran-
script corresponds with high promoter meth-
ylation of GATA4 (Met+ group) versus UMet+ 
group (P = 0.0001). GBMs from the unmethyl-
ated cohort (Umet+ group) that did not have 
GATA4 transcript or high promoter methyla-
tion were subjected to exon sequencing in E. 
(D) GATA4 promoter-luciferase construct  
was transfected in NHA and GBM cell lines 
and measured for luciferase activity over 72 h. 
A 600-bp product of the GATA4 luciferase 
promoter was amplified using PCR and ana-
lyzed for methylation by bisulfite sequencing. 
The percentage of methylation is listed below 
the bar graph for 24 and 72 h (*, P < 0.001). 
(E) Somatic GATA4 mutations identified in 
GBM samples from C. (F) Schematic, location 
of GATA4 mutations, Zinc finger (Zn), nuclear 
localization sequence (nls), and transactiva-
tion domain (TAD). Introduction of mutations 
into WT GATA4 by site directed mutagenesis 
are shown. These mutant constructs were 
cotransfected into U87 cells with a P21-CIP1 
luciferase construct containing two GATA responsive elements. Luciferase readings were measured 24 h after transfection and compared with WT GATA4 
and negative controls with mean and SEM reported (*, P < 0.05). All experiments were performed in triplicate, with D and E showing the mean ± SEM. 
Bisulfite sequencing analysis was determined by sequencing of 10–15 individual clones per sample.692 GATA4 represses astrocytoma formation | Agnihotri et al.
nucleotide polymorphism (SNP) markers flanking the muta-
tions (Fig. S2, A–C). Thus, GATA4 silencing in GBMs is pri-
marily through promoter methylation and somatic mutations 
with accompanying LOH.
Loss of GATA4 promotes HGA formation in vitro and in vivo
Because GATA4 was lost in the mouse GFAP:V12Ha-Ras 
HGAs and majority of human GBM lines and specimens, we 
postulated that GATA4 serves as a TSG in GBMs. First, loss of 
Gata4 in RasB8 P0 nontransformed astrocytes promoted 
proliferation and transformation in vitro (Fig. S3, A–C). The 
transformation synergy was not restricted to activated Ras 
because NHA + hTERT immortalized astrocytes expressing 
E6/E7 oncoproteins (to inhibit both TP53 and RB pathways) 
were also transformed in vitro by shRNA-mediated GATA4 
knockdown (Fig. S3, A–C). To further test our postulate, we 
generated two stable GATA4 shRNA NHA + hTERTs lines 
(nontransformed astrocytes expressing GFAP and no NESTIN), 
which resulted in increased proliferation but not transforma-
tion as measured by soft agar assay (Fig. S3 D and not depicted). 
However, in combination with V12Ha-Ras, to mimic aber-
rantly expressed Ras in GBM through NF1 loss or aberrant 
receptor activation (TCGA network, 2008), we observed that 
loss of GATA4 promoted not only proliferation but also 
growth in soft agar (Fig. 3 A and Fig. S3 E, P = 0.0001). This 
tumorigenic  phenotype  of  the  NHA-V12Ha-Ras-GATA4 
shRNA1 cells was rescued by expressing GATA4 cDNA lack-
ing part of the 3UTR to which the shRNA1 was directed 
against (Fig. 3 A and Fig. S3 E, P = 0.001).
NHA-V12Ha-Ras-GATA4 shRNA1 cells were then in-
jected intracranially into NOD-SCID mice (n = 5) with 
NHA-V12Ha-Ras-GATA4 scrambled shRNA cells as con-
trols. The control cell–injected mice survived without any 
tumors when evaluated at 60 d, which is consistent with the 
nontumorigenic phenotype previously reported for NHA-
V12Ha-Ras cells (Sonoda et al., 2001; Fig. 3 B, top left).   
In contrast, mice injected with NHA-V12Ha-Ras-GATA4 
shRNA1 cells formed tumors (5/5) and died from HGAs   
by 31 ± 7 d (Fig. 3 B, all except top left). The HGAs had 
elevated Ki-67 index and cyclin D1 (CCND1) expression 
and reduced expression of the cell cycle inhibitor P21CIP1 
(Fig. 3 B). These tumors did not express the differentiated 
astrocyte marker GFAP but had increased levels of NESTIN,   
a marker for neuroglial progenitor cells which is highly ex-
pressed in human GBMs (Fig. 3 B, middle row, left and middle). 
Primitive neuroectodermal tumors (PNETs) also lack GFAP 
expression but express high NESTIN levels, but the tumors 
were not PNET based on tumor morphology and lack   
of the PNET/neuronal markers NeuN and Synaptophysin 
(Fig. S3 F). GFAP immunohistochemistry (IHC) analysis of 
47 GBMs (serial sections of GBMs stained for GATA4 in 
Fig. 1 D) demonstrated that loss of GATA4 was associated 
with loss of GFAP (Fig. S5, A and B, P = 0.0087, Fisher’s exact 
test). In addition, GATA4 protein was enriched in GFAP 
promoter by chromatin immunoprecipitation (ChIP) analy-
sis (Fig. S5 C).
promoter has two dense CpG islands, which are sites of in-
creased methylation (Fig. 2 A). Methylation-specific (MSP) 
PCR, which is able to differentiate nonmethylated and meth-
ylated products of the GATA4 promoter, demonstrated that 
the methylated product was amplified from all human GBM 
lines lacking GATA4 expression (Fig. 2 A). In contrast, normal 
human brain (NHB) and NHA had predominantly the non-
methylated product (Fig. 2 A). Treatment of several GBM lines 
with 5-aza-2’-deoxycytidine, an inhibitor of DNA methyltrans-
ferases, restored GATA4 protein expression (Fig. 2 B). We next 
performed MSP-PCR on bisulfite-treated DNA isolated 
from GBM operative samples lacking GATA4 at the transcript 
level (Fig. S1 B). 13/20 of these GATA4-negative samples had a 
methylated product amplify using MSP-PCR (Fig. S1 C).   
To further validate GATA4 promoter methylation, bisulfite 
sequencing, which has increased sensitivity compared with 
MSP-PCR, was used to analyze 36 CpG islands in the GATA4 
promoter of GBM cell lines and specimens (Fig. 2 C). GBM 
samples and GBM cell lines that had methylated MSP prod-
ucts (Met+) had a significant degree of promoter methyla-
tion compared with GBM samples that had unmethylated 
MSP products (UMet+) as analyzed by bisulfite sequencing   
(P = 0.0001; Fig. 2 C).
To determine the functional significance of GATA4 meth-
ylation, we performed in vitro and in vivo assays to monitor 
the effect of promoter methylation. The proximal GATA4 
promoter (1,000 bp) was cloned to regulate a luciferase re-
porter gene (GATA4:Lux). In vitro methylation of GATA4:
Lux significantly reduced luciferase activity in NHA, U87, 
and T98G GBM cells (P = 0.001; Fig. S1, D and E). To test 
active GATA4 promoter methylation, the GATA4:Lux con-
struct was transfected in to U87, T98G, and NHA cells. Within 
72 h of transfecting GATA4:Lux into U87 and T98G cells, 
there was reduced luciferase expression, compared with the 
24-h time point (Fig. 2 D, P = 0.001). In contrast, luciferase 
expression in NHA cells that had unmethylated GATA4 re-
mained unchanged (Fig. 2 D). Bisulfite sequencing of CpG 
islands of the GATA4:Lux construct at 72 compared with   
24 h demonstrated significant methylation (37 and 29% for 
U87  and T98G  cells,  respectively  compared  with  5%  for 
NHAs at 24 h; Fig. 2 D; Fig. S1 F). The bisulfite sequencing 
primers used were specific to the transgene construct and not 
endogenous GATA4 (Fig. S1 G).
To determine alternate methods of gene silencing, we 
subjected the 7/20 GBMs in which the GATA4 transcript 
was absent, but without promoter methylation, to exon se-
quencing. We identified three novel insertion/deletion (indel) 
mutations that resulted in frameshifts. These mutations were 
somatic and not germline because the mutations were not found 
in matched patient blood samples (Fig. 2 E). The mutations were 
located in the Zinc finger domains as well as the C terminus of 
GATA4 (Fig. 2 F). Site-directed mutagenesis corresponding 
to these three mutations on WT GATA4 cDNA resulted in 
loss of GATA4 function, as they could not activate a P21-CIP:
Lux construct (Fig. 2 F, P = 0.001). Loss of heterozygosity 
(LOH) accompanied these mutations, as determined by single JEM VOL. 208, April 11, 2011 
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other relevant GBM genetic altera-
tions promotes HGA formation with 
dedifferentiation.
GATA4 suppresses GBM 
transformation in vitro and in vivo
Because  loss  of  GATA4  promoted 
transformation of NHAs, we hypoth-
esized that reexpression of GATA4 in GBM cells could re-
verse the transformed phenotype. To test this hypothesis, four 
human GBM lines of various genetic alterations (Fig. S4 A, 
summary of alterations) were transiently transfected to express 
GATA4 under the CMV promoter (Fig. 4, A and B). GATA4 
expression  reduced  proliferation  in  all  four  GBM  lines  as 
measured by BrdU incorporation, with accumulation of cells 
in G1 phase of cell cycle (Fig. 4 A and Fig. S4 B). We also   
silenced  GATA4  expression  in  SNB-19  cells,  the  only   
human GBM cells we tested that endogenously express GATA4 
(Fig. 1 B), SNB-19 cells, have a slow proliferation rate com-
parable with that of NHAs. Silencing of GATA4 in these 
SNB-19 cells increased proliferation rates similar to U87 
and T98G  cells,  which  do  not  express  any  endogenous 
GATA4 (Fig. S4 F).
GATA4 expression in the four GBM cells tested without 
endogenous GATA4 expression resulted in reduced cyclin 
Real-time quantitative (q) RT-PCR analysis of the trans-
formed  NHA-V12Ha-Ras-GATA4  shRNA1  cells  demon-
strated loss of GATA4 and GFAP as noted in the previous 
paragraph (Fig. S3 G). In addition, these cells had increased 
levels of markers such as NESTIN, SOX2, and Musashi1 
(MSI1), which are known to be associated with brain tumor 
cell markers. Our observation of GATA4 loss with activated 
Ras up-regulated putative brain tumor stem cell markers led 
us to hypothesize that these cells acquired progenitor-like 
characteristics. In direct support of this, NHA-Ras cells 
with  knockdown of GATA4, but not NHA-Ras control 
cells, were able to form neurospheres (Fig. 3 D, P < 0.0001) 
in neural progenitor growth conditions and acquired the 
ability to differentiate into the three major CNS cell lin-
eages: astrocytes, neurons, and oligodendrocytes, based on 
marker expression, when grown in differentiation conditions 
(Fig. 3 E). In summary, loss of GATA4 in cooperation with 
Figure 3.  Loss of GATA4 promotes trans-
formation. (A) NHAs expressing activated Ras 
were transfected with control or GATA4- 
specific shRNA, with or without an shRNA-
resistant GATA4 construct (GATA4 rescue). 
Left, GATA4 expression measured by Western 
blotting. Right, BrdU incorporation measured 
on indicated days. *, P = 0.02. (B) NOD-SCID 
mice were subjected to intracranial xenograft 
with cells described in A. Brains were analyzed 
by IHC. 0/5 mice injected with shRNA control 
developed tumors (top left). All other panels 
refer to mice injected with GATA4 shRNA1 
(5/5). Bars: (top row, left and middle) 500 µm; 
(middle row, left) 50 µm; (all others) 25 µm. 
(C) Expression of indicated surface markers 
was quantified from staining shown in B from 
five mice. Mean and SEM are represented.  
(D) Cells described in A were cultured in neu-
ral progenitor growth conditions for days. 
Representative neurospheres are shown.  
*, P < 0.0001. (E) Neurospheres from D were 
cultured under conditions promoting differ-
entiation into astrocytes (indicated by GFAP 
expression), neurons (indicated by TUJ1  
expression), and oligodendrocytes (indicated 
by O4 expression). Cells were stained with the 
indicated antibodies, DAPI, and nuclear stain. 
Bar, 16 µm. A, D, and E were performed in 
triplicate with mean and SEM reported where 
appropriate. B and C are representative stains 
from five mice.694 GATA4 represses astrocytoma formation | Agnihotri et al.
expressing HA-tagged ubiquitin (HA-UB). Only under GATA4-
expressing conditions was HA-UB directly incorporated 
into CCND1 (Fig. S4 E). The change in CCND1 and P21CIP1 
protein levels corresponded with reduced cell proliferation 
and a significant increase of cells in the G1 phase of cell   
cycle  (Fig.  4  D  and  Fig.  S4  C). To  determine  whether   
direct loss of CCND1 and/or overexpression of P21CIP1 
resulted in the same phenotype as exogenous GATA4 ex-
pression,  these  alterations  were  introduced  in T98G  cells. 
Similar to exogenous GATA4, reduction of CCND1 or in-
duction of P21CIP1 led to a significant decrease in prolifera-
tion, which was comparable to expression of GATA4 alone 
(Fig. 5, A and B; ANOVA, P < 0.01). However, only GATA4-
expressing T98G cells were sensitized to cell death when 
exposed to temozolomide, a standard chemotherapeutic in 
GBM treatment (Fig. 5 C).
D1 expression and increased levels of the tumor suppressors 
P21CIP1P15INK4B (Fig. 4 B). The induction of cell cycle inhibi-
tors and cyclins by other GATA transcription factors has been 
previously demonstrated by us and others (Perlman et al., 1998; 
Setogawa et al., 2006; Agnihotri et al., 2009); however, our 
observation of the induction of P21CIP1 or attenuation of 
CCND1 by GATA4 has not been reported.
We next generated a stable U87 GBM cell line expressing 
GATA4 under a doxycycline-inducible promoter (Fig. 4 C). 
Induction of GATA4 by doxycycline attenuated levels of cyclin 
D1 with induction of P21CIP1 (Fig. 4 C). Decreased expression 
of CCND1 by GATA4 was not at the transcriptional level but 
through increased ubiquitination by the 26s proteosome 
(Fig. S4D), as it was reversed by the proteosomal inhibitor 
MG132. Furthermore, to determine direct ubiquitination of 
CCND1, U87 cells were transfected with an expression plasmid 
Figure 4.  Re-expression of GATA4 suppresses cell proliferation and in vivo tumor growth. (A) Transient expression of GATA4 under a constitutive 
active CMV promoter or empty vector control (EV) decreases proliferation in several GBM cell lines of varying genetic backgrounds. *, P < 0.01 (B) Tran-
sient expression of GATA4 leads to attenuation of cyclin D1 with increased levels of P21CIP1 and P15INK4B. (C and D) Doxycycline was added to U87 GBM 
cell line expressing GATA4 under a doxycycline-inducible promoter. (C) At indicated time points, GATA4, P21CIP1, and CCND1 were measured by Western 
blotting. (D) At the indicated times, cells in culture were counted. *, P = 0.001. (E) Survival curve of NOD-SCID mice were injected with intracranial xeno-
grafts of U87 cells with GATA4 under doxycycline (DOX)-inducible promoter. Mice were continually given doxycycline in drinking water (GATA4 on, n = 10) 
or no doxycycline (GATA4 off, n = 10). (F) Immunohistochemical analysis of protein markers from tumors of mice not given dox (no GATA4) versus mice 
given dox (GATA4). Bars: (first H&E column) 500 µm; (second [magnified] H&E column) 50 µm; (GATA4, P21-CIP1, and ki67 columns) 25 µm. (G) Quantifi-
cation of protein staining from F. n = 5 mice. *, P < 0.01. Mean and SEM are shown. A and D were performed in triplicate with mean and SEM reported.JEM VOL. 208, April 11, 2011 
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vector control lines cells grown in stem cell media conditions 
(Fig. S5 E). G179 GATA4-expressing lines were also sensitized 
to cell death when exposed to temozolomide (Fig. S5 F; P = 
0.016). In addition to reduced proliferation, G179 GATA4- 
expressing cells had significant reduction of several candidate 
brain tumor stem cell markers: NESTIN, SOX2, and MSI-1 
(Fig. 5 E). No changes in CD133 expression were observed. 
Lastly, we observed increased differentiation potential of G179 
GATA4-expressing lines under differentiation conditions (stem 
cell media + 1% FBS) with significant increase of GFAP (astro-
cyte lineages) and TUBB3 (neuronal lineages) compared with 
controls (Fig. 5 F). Loss of GATA4 in our nontransformed   
HF-240 line was insufficient to increase proliferation (Fig. S5 E) 
but did impair NESTIN, GFAP, and TUBB3 expression during 
differentiation conditions (Fig. S5, G and H).
To complement our findings in GBMs, GATA4 loss was 
observed in several medulloblastoma and non-CNS tumor 
cell lines such as breast, lung, and prostate (Fig. S6, A and B). 
Stable expression of GATA4 in PC3 (prostate), A549 (lung), 
and MD-231 (breast) resulted in decreased proliferation and 
reduced  anchorage-independent  growth  (Fig.  S6,  C–F).   
In summary, transient or stable induction of GATA4 leads to 
diminished cellular proliferation and reduced transformation 
in vitro and in vivo.
Intracranial injection of 2.5 × 105 inducible U87 GATA4 
cells in NOD-SCID mice was undertaken to determine   
in vivo growth effects of GATA4. All 10 of the control mice 
( doxycycline) died of HGAs at 32.8 ± 6.2 d (Fig. 4 E).   
In comparison, the 10 mice receiving doxycycline in their drink-
ing water were all viable and symptom free when sacrificed 
at 120 d. Necropsy analysis demonstrated no brain tumors 
in seven mice, whereas three mice had small tumor growth 
with reduced proliferation and increased levels of GATA4 and 
P21CIP1 (Fig. 4, F and G).
We investigated the status of GATA4 in GBM brain tumor 
initiation cells (BTICs), which are postulated to be responsible 
for tumor initiation and maintenance and resistance to therapy 
(Alcantara Llaguno et al., 2009). These BTICs are able to self-
renew, proliferate, and give rise to different lineages (Singh et al., 
2004; Stiles and Rowitch, 2008). We screened two GBM BTIC 
lines generated from operative tissue as previously described 
(Pollard et al., 2009). G179 had significant reduction of GATA4 
at the RNA and protein level compared with NHA and HF-240, 
a nontransformed neural stem cell line (Fig. 5 D). We next gen-
erated a stable G179 GATA4-expressing line (Fig. S5 D) and 
examined the effect on proliferation and sensitivity to temo-
zolomide. G179 cells expressing GATA4 had significant reduc-
tion in proliferation by day 5 compared with G179 empty 
Figure 5.  GATA4 negatively regulates 
GBM growth. (A) Western blot demonstrat-
ing protein levels of GATA4, P21-CIP, CCND1, 
and APNG in T98G cells under varying treat-
ments. MGMT was used as a loading control. 
(B) BrdU assay of T98G cells by modulation of 
GATA4, P21-CIP, or CCND1. *, P < 0.01 
(ANOVA). (C) GATA4-mediated sensitivity to 
100 µm temozolomide in vitro (T98G cells;  
*, P = 0.001, ANOVA). Cell death under non- 
temozolomide was statistically insignificant  
(P > 0.05, ANOVA). (D, Top) qRT-PCR GATA4 
expression in brain tumor initiating cells 
G144, G179 compared with NHAs, normal 
neural stem cells (NSC), and the embryonic 
stem cell line (H9). (D, Bottom) Western blot 
assessing GATA4 protein status in the lines 
mentioned for D, Top. *, P > 0.05. (E) qRT-PCR 
of neural stem cell markers in G179 cells.  
Cells were grown in neural stem cell media.  
*, P < 0.01. (F) qRT-PCR of the lineage mark-
ers, GFAP (astrocytic), NKX2.2 (oligodendro-
cytic), and TUBB3 (neuronal). *, P < 0.01 in 
G179 cells. Cells were placed in differentiation 
conditions (neural stem cell media + 1% fetal 
bovine serum) for 12 d before RNA extraction.  
All experiments were performed in triplicate 
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of GATA4, we transiently transfected 
U87 cells with a GATA4 cDNA ex-
pression construct and two P21CIP1 
siRNAs (Fig. 6 C). Decreased P21CIP1 
expression in these U87 cells signifi-
cantly blocked, but did not eliminate, 
the ability of GATA4 to reduce pro-
liferation (Fig. 6 D). Loss of P21CIP1 
by itself without GATA4 increased 
proliferation of U87 cells compared with controls. Because 
U87 cells are TP53 WT, and P21CIP1 is also a direct target of 
TP53, we undertook experiments to decipher whether the 
induction of P21CIP1 was dependent on TP53 in the context 
of GATA4. Toward this, addition of doxorubicin resulting in 
activation/phosphorylation of p53 at Ser15 increased P21CIP1 
RNA and protein expression in U87 cells, which was further 
augmented by GATA4 (Fig. 6 E; and Fig. S7, B and C). In the 
absence of TP53 by shRNA silencing, GATA4 still induced 
P21CIP1 expression (Fig. 6 E; and Fig. S7, B and C). Addition-
ally, in U373 GBM cells that are mutant for TP53, GATA4 
was able to transactivate P21CIP1:Lux constructs with restora-
tion of WT TP53 in the U373 cells further increasing P21CIP1:
Lux activity (Fig. 6 F). Collectively, activation of P21CIP1 by 
GATA4 with reduced or mutant TP53 suggests that GATA4 
activation of P21CIP1 is independent of TP53. However, the 
strongest activation was in the presence of both TP53 and 
GATA4. Because GATA4 and TP53 are not transcriptional 
targets of each other (Fig. S7 D), additional TP53-independent 
mechanisms of P21CIP1 are likely.
GATA4 mediates its tumor suppressive effect  
through P21CIP1
GATA4-mediated decreased proliferation and increased the 
percentage of cells in G1, strongly suggesting a role in regulat-
ing cell cycle. GATA4 expression in several GBM cell lines 
consistently increased P21CIP1 protein levels (Fig. 4 B). We 
sought to determine whether P21CIP1 was a direct target of 
GATA4 as P21CIP1 transcript levels increased with GATA4 
(Fig. S7 A). We focused on P21CIP1 induction by GATA4 in 
GBMs because our prior studies had already demonstrated 
that GATA4 induces P15INK4B in normal human and mouse 
astrocytes (Agnihotri et al., 2009). The P21CIP1 promoter has 
several GATA binding elements, two of which were enriched 
by ChIP analysis (Fig. 6 A). Furthermore, transactivation lu-
ciferase assays with a 2.6-kb P21CIP1:Lux construct induced 
luciferase expression in the presence of GATA4 (Fig. 6 B). 
Site-directed mutagenesis to eliminate the GATA elements in 
the two promoter luciferase constructs (MS1/MS2 for P21CIP1) 
ablated the ability of GATA4 to drive luciferase expression 
(Fig. 6 B). To determine if P21CIP1 is a key downstream effector 
Figure 6.  P21CIP1 is a direct target of 
GATA4. (A) ChIP assay of GATA4. GATA4 is 
enriched in P21CIP1 promoter regions con-
taining GATA binding elements (top, U87 
cells). (B) P21-CIP1 luciferase construct wt 
or constructs with GATA sites mutated were 
transfected into U87 cells with or without 
WT GATA4. Luciferase readings were taken 
48 h after transfection. *, P < 0.001. GATA 
fails to activate luciferase expression when 
both GATA sites are mutated (MS1 and 
MS2). *, P < 0.001 compared with WT con-
trol P21-luciferase construct. (C and D) Si-
lencing of P21CIP1 with overexpression of 
GATA4 rescues the antiproliferation effect 
of GATA4 but not to parental levels. *, P < 
0.001; **, P = 0.002. Loss of P21CIP1 by itself 
further increases proliferation in U87 cells. 
***, P < 0.001. (E) Western blot demonstrat-
ing overexpression of GATA4, loss of P53, 
and changes to P21-CIP1 levels. Doxorubicin 
was used to activate TP53. (F) P21-CIP1 
luciferase assay in U373 cells (mutant TP53), 
and GATA4 and WT TP53 lead to a synergis-
tic increase of luciferase expression.  
*, P = 0.001, lane 5 compared with lanes  
2 and 3. Experiments were performed in 
triplicate with mean and SEM reported.JEM VOL. 208, April 11, 2011 
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from GATA4 expression (Fig. 7 B). 
A surprising finding was that levels   
of MGMT were not altered (Fig. 7 C). 
Excluding O6 guanine methylation, 
which is repaired by MGMT, temo-
zolomide alkylates DNA at the N7  
position of guanine and the N3 posi-
tion of adenine (Denny et al., 1994), 
lesions which are repaired by alkyl-
purine-DNA-N-glycosylase  (APNG; 
Hang et al., 1997). Transient trans-
fection of GATA4 reduced levels of 
APNG (Fig. S7 G) in all established 
and primary GBM lines tested. Furthermore, T98G and 
GBM6 lines stably expressing GATA4 decreased APNG 
levels with no reduction of MGMT expression (Fig. 7 D). 
To directly test the role of APNG in temozolomide resistance, 
we treated T98G cells with MGMT and APNG siRNA 
individually and in a double knockdown (Fig. 7 E). Loss of 
APNG or MGMT had no effect on cell viability under nor-
mal conditions (unpublished data; P > 0.05, ANOVA). Under 
temozolomide conditions, compared with control cells, loss 
of APNG sensitized cells to cell death in a dose-dependent 
manner (Fig. 7 F; P < 0.0001). Co-loss of both MGMT and 
APNG resulted in enhanced sensitization to temozolomide-
induced cell death (Fig. 6 F). APNG siRNA2 and MGMT 
siRNA2 had similar results (unpublished data). Interestingly, 
GATA4 regulation of APNG is not at the transcript level, sug-
gesting an alternative method of GATA4 regulating APNG 
(Fig. S7 H). Together, these results suggest that GATA4 sensi-
tization of GBM cells to temozolomide is mediated through 
loss of APNG.
GATA4 sensitizes GBM cells to temozolomide independent 
of O-6-methylguanine-DNA-methyltransferase (MGMT)
The negative survival associated with GATA4 loss in GBM 
patients led us to hypothesize that GATA4 loss may be involved 
in chemotherapeutic resistance, such as temozolomide. Tran-
sient expression of GATA4 decreased viability of U87 and 
T98G GBM cells to temozolomide in a dose-dependent man-
ner (Fig. 7, A and B). The reduced cell viability correlated 
with increased apoptosis as cells subjected to GATA4 and   
temozolomide had a significant increase of the sub-G1 popula-
tion and increased levels of cleaved PARP (Fig. 7 C; and 
Fig. S7, E and F). We next used established and primary GBM 
cell lines (Sarkaria et al., 2006) to evaluate whether the GATA4-
mediated sensitization was dependent on TP53 status and 
MGMT, the DNA repair enzyme which is most often im-
plicated  in  temozolomide  resistance  (Hegi  et  al.,  2004, 
2005). T98G plus GBM6 (mutant TP53 and MGMT posi-
tive) and U87 plus GBM8 (wtTP53, MGMT negative) cells 
demonstrated similar sensitization to temozolomide resulting 
Figure 7.  GATA4 sensitizes GBM cells 
to temozolomide. (A and B) GATA4 sensi-
tizes T98G and U87 cells to temozolomide.  
*, P < 0.01 from 40–500 µm. (C) Immuno-
blotting shows GATA4 in presence of temo-
zolomide increased cleaved PARP with no 
changes in MGMT observed. GATA4 reduces 
levels of the DNA repair enzyme APNG in 
GBM cell lines and primary xenograft GBM 
cultures. (D) Stable GATA4 expression in 
MGMT-expressing T98G cells or GBM6 xe-
nograft cells led to reduced levels of APNG 
and increased levels of cleaved PARP when 
exposed to temozolomide. (E) Immunoblot 
showing MGMT and APNG knockdown 
when treated with siRNA compared with 
controls in T98G cells. (F) Trypan blue cell 
death assay of APNG, MGMT, or combina-
tion knockdown compared with siRNA con-
trols. *, P < 0.0001 in T98G cells. A, B, and F 
were performed in triplicate with SEM re-
ported. Experiments in C–E were performed 
in triplicate with representative Western 
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with the C1.1 region of the GFAP promoter. This is of high 
interest, as this region contains a highly conserved GATA ele-
ment among several mammalian species (Lee et al., 2008).   
Although this may imply GFAP regulation by GATA4, the 
co-loss may also arise as a result of the fact that GATA4 and 
GFAP are both targeted for epigenetic silencing (Restrepo et al., 
2011; this paper). GATA4’s role in embryonic stem cell and 
endoderm differentiation has been well studied. The ability of 
GATA4 reexpression in the BTIC line G179 illustrated that 
GATA4 has a prodifferentiation effect in GBM BTIC lines 
with decreased proliferations. This is further complemented 
by the fact that NHAs expressing activated RAS and loss of 
GATA4 acquired progenitor-like phenotypes and that loss of 
GATA4 in the nontransformed neural stem cell (HF-240) re-
duces astrocytic and neuronal expression markers GFAP and 
TUBB3 at the RNA level. Although HF-240 cells express 
GATA4, its expression is lower compared with differentiated 
astrocytes (NHAs). Therefore, the exact role of GATA4 and 
the relevance of expression level remain to be elucidated in 
neural stem cells.
We also observed that GATA4 loss is a negative survival 
factor in GBM patients treated with current standardized care 
involving surgery, radiation, and temozolomide. Our results 
demonstrate sensitization of GBM cells by expression of GATA4, 
which is independent of TP53 and MGMT status of the cells. 
Our observation is that APNG, which is involved in repairing 
another site of DNA methylation by temozolomide, is of poten-
tial therapeutic interest in perhaps modulating GBM sensitiv-
ity to temozolomide and other alkylating agents independent 
of current interests in MGMT. This last point is of unusual inter-
est, as it demonstrates how DNA repair enzymes, caretakers of 
DNA damage in normal cells, can be a major hurdle and con-
tribute to chemotherapeutic resistance in cancer cells, not only 
limited to GBM. This is of clinical importance, as it provides 
a potential therapeutic target and offers an alternative explana-
tion as to why some MGMT-positive patients are still respon-
sive to temozolomide or why some MGMT-negative patients 
are resistant to temozolomide. Although we were unable to 
determine how GATA4 attenuates APNG, we hypothesize 
that it may be at the protein level, such as in ubiquitination by 
activation of unknown GATA4-regulated E3 ligases.
Furthermore, GATA4 loss in medulloblastoma cell lines 
and various other cancer cell lines at the protein level (Fig. S6, 
A and B) may suggest that GATA4’s effects are not restricted 
to just GBM. In direct support of this, stable restoration of 
GATA4 in lung, prostate, and breast cancer cell lines sup-
pressed proliferation. These findings suggest that GATA4 ex-
erts TSG properties in other cancers, in addition to our findings 
in GBM, and that the role of GATA4 in these cancers where 
it is silenced should be further investigated.
In summary, we have identified and validated a novel 
human TSG in human astrocytomas, with work initiated from 
well characterized mouse models. These replenishable mouse 
models, with limited genetic variability, not only facilitate our 
understanding of and interactions with known genetic altera-
tions in human cancer but also serve to elucidate novel genetic 
DISCUSSION
The identification and validation of GATA6 as a TSG in human 
GBMs (Kamnasaran et al., 2007) led to our interest in other 
GATA transcription factors, namely the GATA4,5,6 subfamily. 
Our expression profiling of GATA4, but not GATA5, dem-
onstrated loss of expression in a majority of human GBM 
lines and specimens. Recent genome-wide studies have also 
reported reduced expression of GATA4 in 70% of samples 
analyzed, with reduced copy number and copy-neutral LOH 
in  5%  of  GBM  samples  (Cancer  Genome Atlas  Research 
Network, 2008; Parsons et al., 2008). In additional support of 
our thesis, we demonstrated ubiquitous expression of GATA4 
in normal embryonic and adult astrocytes, where it functions 
as a negative regulator of astrocyte growth (Agnihotri et al., 
2009). Direct evidence comes from data presented in this 
manuscript where GATA4 fulfills the hallmarks of a TSG in 
cancer development (Haber and Harlow, 1997), specifically 
human astrocytomas. GATA4 expression was lost in human 
GBMs through promoter methylation and somatic mutations 
associated with LOH. Interestingly we observed no transcript 
associated with these mutations. Given the fact that these 
mutations occur in exons near intron/exon boundaries, it is 
highly suggestive that these mutant transcripts are targeted for 
destruction by the mRNA nonsense-mediated decay path-
way (Maquat, 2004). Loss of GATA4 in human and mouse 
astrocytes promoted HGA formation in vivo, in conjunction 
with other genetic alterations. Reexpression of GATA4 sup-
pressed astrocytoma growth in vivo. It is of interest that we 
observed a higher frequency of GATA4 loss in LGAs (50%) 
compared with our result for GATA6 (20%). This, along 
with the present findings that GATA4 can negatively regulate 
brain tumor–initiating cells, suggests that GATA4 loss is an 
earlier event in astrocytoma genesis.
Our study is the first mechanistic investigation of the 
tumor-suppressive actions of GATA4, whose loss has been docu-
mented in other human cancers (Cai et al., 2009; Hellebrekers 
et al., 2009; Hua et al., 2009). We identified P21CIP1 as a direct 
transcriptional target of GATA4, with attenuation of the 
potent oncogene cyclin D1 through ubiquitination. This is of 
great interest, as GATA transcription factors have never been 
implicated in regulation of ubiquitination, a biological pro-
cess which is poorly characterized in GBM. Our data demon-
strates that induction of P21CIP1 is not entirely dependent on 
TP53, but additional pathways are likely to be used by GATA4 
to induce P21CIP1 and inhibit cell cycle and astrocytoma pro-
liferation. In addition, the fact that removal of P21CIP1 did not 
eliminate all of the antiproliferative effects of GATA4 suggests 
that mechanisms outside of P15INK4B and P21CIP1 exist for 
GATA4-mediated growth suppression. Identification of these 
target genes are of critical interest. In a recent study, four sub-
types of primary GBM based on gene expression profiling 
were identified, with the proneural subtype having the great-
est decrease of GATA4 (Verhaak et al., 2010).
Loss of GATA4 also correlated with loss of GFAP at the 
protein level, which is a surrogate marker for GBM tumor 
differentiation. Interestingly, GATA4 was found to be associated JEM VOL. 208, April 11, 2011 
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OriGene) was delivered using Fugene HD transfection reagent (Roche). 
pCMV6-XL4 with no cDNA insert was used as an empty vector control. 
Gene-specific siRNA (Integrated DNA Technologies and QIAGEN) and 
scramble siRNA controls (all-star scramble siRNA; QIAGEN) were delivered   
to cultured cells using HiPerFect transfection reagent (QIAGEN) to a final 
concentration of 20 nM. Please refer to Table S1 for all siRNA sequences. For 
transient knockdown of TP53, TP53 shRNA clones in pLKO.1 vectors were 
obtained from Thermo Fisher Scientific. Vectors were transfected into U87 
cells using Fugene HD at a ratio of 3:1 Fugene HD/DNA. TP53 full-length 
cDNA was a gift from M. Irwin (SickKids Hospital). P21CIP1 cDNA expres-
sion vector was purchased from SIDNET (SickKids Hospital).
Bisulfite sequencing and methylation PCR. DNA collected from cell 
lines or GBM operative samples was bisulfite treated and purified using the 
EZ DNA methylation kit (BaseClear; Zymogen). For MSP-PCR, 50 ng 
DNA was used for template using GATA4 MSP-specific primers. For Bisul-
fite sequencing, GATA4 BSP-PCR–specific primers were used and DNA 
was gel extracted and purified. DNA was cloned into a PCR TOPO 2.1 se-
quencing vector (Invitrogen). A minimum of 10 clones were analyzed per 
cell line or GBM samples with NHA and NHB used as controls. Data were 
analyzed using BiQ analyzer software (v2.0; Bock et al., 2005). PCR condi-
tions and primers were as previously described (Guo et al., 2004).
SNP marker analysis for LOH. PCR primers spanning GATA4 intra-
genic SNP markers were used to amplify PCR products of 200–300 bp. 
Tumours in which mutations were identified had several SNP markers ana-
lyzed and compared with SNP markers in patient matched blood. All se-
quences were verified in triplicate using three independent PCR reactions 
and sequencing reactions. See Table S1 for primer sequences.
In vitro methylation assay and luciferase assays. In brief, a 1-kb pro-
moter fragment was amplified from a GATA4 BAC (GATA4 BAC: RP11-
241B23, obtained from The Centre of Applied Genomics at SickKids Hospital). 
The GATA4 1-kb promoter was cloned into a promoter less pGL 4.0   
luciferase construct (Promega) or was treated with Sss1 methyl transferase 
(New England Biolabs, Inc.) incubated at 37°C at 1 h, supplemented with 
160  µM  S-adenosylmethionine  before  being  cloned  into  pGL  4.0. The 
P21CIP1:Lux construct was obtained from B. Vogelstein (John Hopkins Uni-
versity, Baltimore, MD) and the P15INK4B Lux construct from P.J. Chiao   
(M. D. Anderson Cancer Center). Primer sequences for site directed muta-
genesis to the GATA sites in these constructs are available in Table S1.
Luciferase assays of various promoter luciferase constructs were per-
formed as follows. 2 µg luciferase construct of interest and 100 ng of control 
Renilla (RLUC; Promega) was transfected into cell lines using Fugene HD. 
Luciferase activity was measured using the Dual-Luciferase Reporter Assay 
System (Promega). Arbitrary luciferase units were normalized to Renilla   
luciferase values. Each transfection was repeated in triplicate.
Real-time PCR analysis. Total RNA isolation was performed using an RNA 
extraction kit total (RNeasy extraction kit; QIAGEN). cDNA was synthesized 
from 100 ng of total RNA using the QuantiTect RT kit which includes DNase 
treatment (QIAGEN). Real-time qPCR was performed on 40 ng cDNA tem-
plate in a final volume of 25 µl using the Chromo4 Real-Time PCR detector 
(Bio-Rad Laboratories) using SYBR green fluorescence. Real-time PCR data 
were analyzed using analysis software (Monitor 3.1.3; Opticon). Data analysis 
was done using the CT method with HPRT1 as a reference/control gene.
Soft agar assay for in vitro transformation. Soft agar plates were poured 
with a base layer of 0.5% agar in 6-well culture plates. 104 cells of various 
modifications and control lines were counted and mixed with equal volume 
0.75% soft agar for the top layer. 4 ml DME + 10% FBS media was poured 
on top of the agar overlay and colonies were counted 14 d after. Soft agar ex-
periments were repeated in triplicate.
Cell death assay. In brief, 105 T98G cells were plated onto 6-well dishes   
in 2 ml DME +10% FBS. Cells were treated with siRNA scramble control, 
two different APNG siRNAs, two MGMT siRNAs, or a combination of 
alterations with gene discovery strategies such as gene trap 
screens. Careful validation in human samples and mechanistic 
studies are required and collectively augment the findings 
from large-scale human cancer initiatives.
MATERIALS AND METHODS
Tumour specimens. NHB, low grade, and GBM operative samples were 
obtained from the IREB-approved Nervous System Tumor Bank at Univer-
sity Health Network (UHN; http://www.braintumourbank.ca/index.html), 
Toronto. Additional GBM-containing tissue microarrays were obtained from 
the MD Anderson Cancer Center (G. Fuller and K. Aldape) and University 
of California, Los Angeles (P. Mischel).
Xenograft studies. Mice were maintained in accordance with UHN in-
stitutional animal protocols. Stereotactic guided intracranial injections in 
NOD-SCID mice were performed by injecting 250,000 cells of NHA-Ras + 
shRNA control, NHA-Ras + GATA4 shRNA1, U87-TRE-GATA into the 
frontal cortex (coordinates were X = 1.0, Y = 1.5, Z = 2.4, with Bregma 
serving as the 0 point for X and Y).
Cell lines and primary cultures. U87 and T98G cell lines were obtained 
from American Type Culture Collection. NHA and NHA + hTERT cells were 
obtained from R.O. Pieper (University of California, San Francisco, San Fran-
cisco, CA) and U373 and D423 cells were obtained from D. Bigner (Duke Uni-
versity, Durham, NC). The cells were grown in DME supplemented with 10% 
FBS at 37°C in a 95% air/5% CO2 atmosphere. Primary mouse astrocytes were 
established from newborn or adult control CD1 mice or the RasB8 mouse 
model as previously described (Luo et al., 2000; Kamnasaran et al., 2007). The 
purity of mouse astrocytes was >95%, as determined by immunofluoresence   
cytochemistry assay with anti-glial fibrillary acidic protein antibody (astrocyte-
specific marker). GBM6 and GBM8 xenograft lines were established from serially 
passaged mice xenografts models as previously described (Sarkaria et al., 2006).
Mutation sequencing. GATA4 exons and neighboring intronic regions 
were amplified using PCR with Hi fidelity Taq (Invitrogen) and sequenced 
at The Centre for Applied Genomics Sequencing Facility (Hospital for Sick 
Children’s Research Institute, Toronto, Ontario, Canada). Mutations identi-
fied were validated in triplicate by three separate PCR reactions and sequencing 
runs. Mutations into WT GATA4 cDNA for functional studies were done 
using the site-directed mutagenesis using the QuikChange XL Site-Directed 
Mutagenesis kit (Agilent Technologies).
Temozolomide and doxorubicin treatment. Doxorubicin (Sigma- 
Aldrich) and temozolomide (Schering-Plough) were used at various concen-
trations (refer to figures) on cell lines with or without GATA4 for investigation 
of effects on cell cycle and apoptosis.
Generation of stable cell lines. The U87 TRE-GATA4–inducible system 
was established by transfecting U87 cells with rtTA (pTET-On advanced 
vector; Takara Bio Inc.) and GATA4 cDNA (clone SC124037; OriGene) 
cloned into pTRE-Tight (Takara Bio Inc.). 250 µg/ml neomycin and 1 µg/ml 
puromycin were used to select for stable pools. T98G and GBM6 GATA4 
stables were generated by cloning GATA4 cDNA into a CMV-IRES-GFP 
vector. 120 h after transfection, cells were sorted for GFP signal by the Sick-
Kids Hospital flow cytometry facility (Toronto, Ontario, Canada). Empty 
vector CMV-IRES-GFP stables in T98G and GBM6 were also created as 
control lines. Stable knockdown of GATA4 in human or mouse cells was ac-
complished by using shRNA hairpins against GATA4 mRNA sequences 
cloned in pSIREN retroQ (Takara Bio Inc.). Cells were transfected with 
various shRNAs, including a scramble shRNA control vector (QIAGEN). 
Puromycin selection was used for stable clones (2 µg/ml). Plasmids were de-
livered using Fugene HD (Roche) at a 3:1 ratio of Fugene/plasmid DNA.
Transient  transfections.  For  GATA4  overexpression,  human  GATA4 
cDNA in a pCMV6-XL4 expression vector (National Center for Biotech-
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(1:1,000; Cell Signaling Technology), ubiquitin (SC-8017; 1:500; Santa Cruz 
Biotechnology, Inc.), and HA antibody (1:500; Abcam). After incubation, 
membranes were washed and incubated with horseradish peroxidase–conjugated 
antibodies against the species the primary antibody was raised against (Bio-
Rad Laboratories). Protein detection was performed by using Chemilumi-
nescence Reagent Plus (PerkinElmer). Blocking and washes were performed 
as per the manufacturers’ specifications.
30 µg of protein lysates were loaded into 10 or 12% SDS-PAGE gels. 
Proteins were then transferred onto PVDF membrane and probed for varying 
proteins: GATA4 (G4; 1:200; Santa Cruz Biotechnology, Inc.), -actin 
(1:5,000; Sigma-Aldrich), p15INK4B (K-18; 1:200; Santa Cruz Biotechnol-
ogy, Inc.), cyclin D1 (1:400; ; Santa Cruz Biotechnology, Inc.), cyclin D2 
(1:400; Abcam), p16INK4A (1:250; Santa Cruz Biotechnology, Inc.), p14ARF 
(1:200; Santa Cruz Biotechnology, Inc.), p19Arf (1:200; Santa Cruz Biotech-
nology, Inc.), and p53 (1:300; Vector Laboratories). Protein detection was 
performed using Chemiluminescence Reagent Plus (PerkinElmer).
Statistical  analysis. All  experiments  were  performed  in  triplicate  with 
means and standard error of the mean or standard deviation subjected to Stu-
dent’s t test for pairwise comparison or ANOVA for multivariate analysis. 
Significance was defined at P < 0.05. Analysis of patient survival was per-
formed using Kaplan-Meier analysis in SPSS software (v15) using three sepa-
rate tests: log-rank (Mantel Cox test) and Breslow (Generalized Wilcoxon 
and Tarone-Ware).
Additional experimental procedures. Cell Cycle, BrdU proliferation assays, 
caspase 3/7 assays, and ChIP assays were done using standard methods as pre-
viously described in detail (Guha et al., 1997; Ding et al., 2001; Shannon   
et al., 2005; Kamnasaran et al., 2007; Agnihotri et al., 2009).
Online supplemental material. Fig. S1 shows loss of GATA4 transcript by 
RT-PCR and loss of GATA4 by promoter methylation. Fig. S2 shows that 
GATA4 mutations are associated with LOH of SNPs flanking mutations found 
in GATA4. Fig. S3 demonstrates that loss of GATA4 promotes transforma-
tion in nontransformed astrocytes. Fig. S4 shows that reexpression of GATA4 
induces cell cycle arrest and promotes ubiquitination of CCND1. Fig. S5 shows 
that GATA4 is associated with the GFAP promoter and loss of GFAP is associ-
ated with loss of GATA4. Overexpression of GATA4 reduces proliferation in 
the brain tumor–initiating cell line G179. Fig. S6 shows that GATA4 represses   
in vitro transformation in breast, prostate, and lung cancer cell lines. Fig. S7 shows 
that GATA4 promotes apoptosis with temozolomide. Table S1 reports all primers, 
shRNA, and siRNA sequences used in this study. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20102099/DC1.
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